Mezigdomide (CC-92480/BMS-986348) is a new medication being tested in this study. It is designed to help treat multiple myeloma, a type of blood cancer, especially in patients whose cancer has returned or has not responded to previous treatments. Mezigdomide works by targeting and destroying cancer cells, which may help slow down or stop the progression of the disease.

Carfilzomib is a medication used to treat multiple myeloma. It works by blocking the action of proteasomes, which are structures inside cells that break down proteins. By inhibiting proteasomes, carfilzomib causes a buildup of proteins in cancer cells, leading to their death. This helps to control the growth and spread of the cancer.

Dexamethasone is a type of steroid medication that is often used in combination with other cancer treatments. It helps reduce inflammation and can also help kill cancer cells. In the context of multiple myeloma, dexamethasone is used to enhance the effectiveness of other treatments and manage symptoms associated with the disease.

Relapsed or Refractory Multiple Myeloma – Multiple myeloma is a type of blood cancer that affects plasma cells, which are a type of white blood cell found in the bone marrow. In relapsed or refractory multiple myeloma, the disease has returned after treatment or does not respond to therapy. The disease progresses as abnormal plasma cells multiply uncontrollably, leading to bone damage, kidney problems, and weakened immune function. Over time, these cancerous cells crowd out healthy blood cells, causing anemia and increased risk of infections. Patients may experience symptoms such as bone pain, fatigue, and frequent infections. The progression of the disease can vary, with periods of stability followed by worsening symptoms.